Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

计划入组 33 人 · 首次发布于 2023 年 10 月 27 日

Good-first: B/F/TAF As First-line ART

计划入组 630 人 · 首次发布于 2024 年 9 月 30 日

Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection

计划入组 150 人 · 首次发布于 2021 年 11 月 17 日

GS-9883 + F + TAF

TAF-001

HMB-TAF

Cwm Taf University Health Board

United Kingdom

AB&B BIO-TECH-B

CWM TAF MORGANNWG UNIVERSITY HEALTH BOARD

United Kingdom

Bictegravir/FTC/TAF Shows Efficacy in HIV Patients with NRTI Resistance After PI-based Therapy Switch

Biktarvy Maintains High Virologic Suppression in Black Adults with HIV Over Five Years

Biktarvy Demonstrates Sustained Efficacy and Safety in HIV/HBV Co-infection Over Three Years